眼科治疗公司 OCUL

Pravin U. Dugel, M.D. has served as Executive Chairman and as a member of our board of directors since February 2024, and as our President and Chief Executive Officer since April 2024. Dr. Dugel previously served as President of IVERIC bio, Inc., or IVERIC, a biopharmaceutical company, from May 2021 to October 2023, and as Executive Vice President, Chief Strategy and Business Officer of IVERIC from April 2020 to May 2021. Prior to IVERIC, Dr. Dugel was a managing partner at Retinal Consultants of Arizona from July 1994 to March 2021. Dr. Dugel previously served on the boards of Oculis Holding AG, a publicly traded biopharmaceutical company from 2020 to May 2024; IVERIC from January 2023 until its acquisition by Astellas US Holdings, Inc. in July 2023; and Aerpio Pharmaceuticals, Inc. from March 2017 until its acquisition by Aadi Bioscience, Inc. in August 2021. Dr. Dugel also served as a clinical professor at the USC Eye Institute in the Keck School of Medicine at the University of Southern California and was a founding member of the Spectra Eye Institute in Sun City, Arizona. Dr. Dugel holds a B.A. from Columbia University in Comparative Literature and Molecular Biology and an M.D. from the UCLA School of Medicine, and he completed his residency in ophthalmology at the USC Eye Institute. He completed a medical retina fellowship at the Bascom Palmer Eye Institute and a surgical eye fellowship at the USC Eye Institute.

Nadia Waheed, M.D. has served as our Chief Medical Officer since June 2024. Since 2011, Dr. Waheed, who is a board-certified retina specialist, has been Professor of Ophthalmology at Tufts University Medical School, where she maintains her appointment. Dr. Waheed also serves as a member of the board of directors for the Boston Image Reading Center, as well as on the board of directors of iOlyx Pharmaceuticals, a privately-held biopharmaceutical company. Dr. Waheed previously served as Chief Medical and Development Officer at Beacon Therapeutics, a biotechnology company focused on serious diseases of the eye that cause vision loss and blindness, from November 2022 to June 2024. Prior to joining Beacon, she served as Chief Medical and Development Officer, Head of Clinical Development at Gyroscope Therapeutics, a biotechnology company working on ophthalmic gene therapies, from December 2019 to July 2022. Dr. Waheed received her M.D. from the Aga Khan University Medical School in Pakistan and her M.P.H. from the Harvard School of Public Health. Dr. Waheed completed her residency and retina fellowship at the Harvard Medical School / Massachusetts Eye and Ear Infirmary.

Donald Notman has served as our Chief Financial Officer since September 2017 and our Chief Operating Officer since September 2024. Mr. Notman previously served as Senior Vice President and Chief Financial Officer of Thrasos Therapeutics, Inc., a biopharmaceutical company, from May 2014 until March 2017 and as a consultant from March 2017 to December 2017. Prior to joining Thrasos Therapeutics, he served as Managing Director and Head of Private Capital Markets of Leerink Swann LLC, an investment bank specializing in health care, from June 2005 to April 2013. Mr. Notman received a B.A. in Economics from Middlebury College and an M.B.A. from The Tuck School of Business at Dartmouth College. Effective as of January 20, 2026, Donald Notman, Chief Financial Officer and Chief Operating Officer (principal financial officer and principal accounting officer) of Ocular Therapeutix, Inc. , is taking a temporary medical leave of absence from the Company. On June 10, 2026 Donald Notman is continuing to serve as Chief Operating Officer of the Company.

Sanjay Nayak, M.B.B.S., Ph.D. has served as our Chief Strategy Officer since February 2024. Dr. Nayak previously served as founder and fund manager of biotechnology-focused private investment fund Sentiv Capital from April 2017 to February 2024. Prior to founding Sentiv Capital, Dr. Nayak was the founder of AnalyzeRx LLC, a healthcare consulting practice, and served as its President from December 2003 to September 2019. Prior to founding AnalyzeRx LLC, Dr. Nayak served as a Director at Strategic Analysis, Healthcare, from April 2000 to December 2003. Dr. Nayak received his M.B.B.S. from Grant Medical College, University of Bombay, India and earned a Ph.D. in pharmacology from Drexel University.

Charles Warden has served as a member of our board of directors since 2008 and as the Lead Independent Director of our board of directors since February 2024. He previously served as the Lead Independent Director of our board from 2014 to July 2019 and as the Chairman of our board from July 2019 to February 2024. Mr. Warden has served as the President and Chief Executive Officer and a director of Aquea Health, Inc., a clinical-stage, ophthalmic medical device company he co-founded, since January 2020. He also has served as a Managing Director at Versant Ventures since 2004. Prior to Versant, he was a General Partner at Schroder Ventures Life Sciences (now SV Life Sciences), where he worked from 1996 to 2004. Previously, Mr. Warden served as an associate with Boston Capital Ventures and as a consultant with Monitor Company. Throughout the course of his career as a venture capital investor, Mr. Warden has been actively involved with multiple medical device and ophthalmic incubators. He serves or has served on the boards of numerous privately-held life sciences companies, several of which have been in the field of ophthalmology. Mr. Warden holds a B.A. from Beloit College and an M.B.A. from Harvard University.

Merilee Raines has served as a member of our board of directors since September 2021. Ms. Raines served as Chief Financial Officer of IDEXX Laboratories, Inc. from October 2003 until her retirement in May 2013. Ms. Raines also served as Executive Vice President of IDEXX from July 2012 until her retirement in May 2013. Prior to becoming Chief Financial Officer, Ms. Raines held several management positions with IDEXX, including Corporate Vice President of Finance, Vice President of Finance and Treasurer, Director of Finance, and Controller. Ms. Raines has served as a member of the boards of directors of Watts Water Technologies, Inc., a publicly-traded global supplier of water technologies and solutions, since February 2011; Excelitas Technologies Corporation, a privately-held photonics company providing sensing and detecting solutions, since August 2018; and TransMedics Group, Inc., a publicly-traded commercial stage medical technology company, since January 2021. She also served as a member of the board of directors of Benchmark Electronics, Inc., a publicly-traded worldwide provider of engineering services, integrated technology solutions and electronic manufacturing services, from May 2018 to June 2021 and Aratana Therapeutics, Inc., a publicly-traded veterinary therapeutics company, from February 2014 until its acquisition in July 2019.

Leslie J. Williams has served as a member of our board of directors since March 2019. Since January 2026, Ms. Williams has served as President and Chief Executive Officer and as a member of the board of directors of DaCapo Brainscience, Inc., a privately-held biotechnology company. From February 2021 to April 2025, she served as the President and Chief Executive Officer and as a member of the board of directors of hC Bioscience, Inc., a privately-held biopharmaceutical company that she co-founded. She also has served as an executive-in-residence for the University of Iowa since 2020 and University of Virginia since 2021, and as an operating partner at Accelerator Life Science Partners since 2020, and advises biopharma companies from time-to-time. Ms. Williams was the founder of ImmusanT, Inc., a biotechnology company, and served as a member of its board of directors and as its President and Chief Executive Officer from its inception in December 2010 until the completion of its reverse merger in December 2019. She served as the President and Chief Executive Officer and as a member of the board of directors of Ventaira Pharmaceuticals, Inc., a specialty pharmaceutical company, from 2004 until 2008. Previously, Ms. Williams also was a venture partner at Battelle Ventures, an early-stage venture capital fund, and served on the boards of directors of Hepregen Inc., a company engaged in the development and marketing of proprietary drug screening products from 2010 to 2013, and of CDI Bioscience, Inc., a cell-line engineering and contract manufacturing company, from 2006 to 2010, and The Capital Network, a non-profit organization providing entrepreneurial education opportunities, from 2010 to 2016. Ms. Williams served as a member of the board of directors of Windtree Therapeutics, a publicly-traded biotechnology company, from February 2021 to August 2024. Since December 2025, she has also served as a member of the board of directors for Axelyf, Inc., a privately held biotechnology company. Ms. Williams also serves as a member of the board of directors of MassBio, a nonprofit organization representing 1,700 biopharma companies in Massachusetts and as a board member of Make-a-Wish Massachusetts and Rhode Island, and as a member of the board of directors of BIO (Biotechnology Innovation organization), a biotechnology advocacy organization. Ms. Williams is also a member of the board of advisors of Coral Sea Clinical Research Institute, an advisory board member of Life Science Cares, a former member of the executive board of the University of Iowa College of Pharmacy, founding Ambassador of BioBoost, founding member of Mass VX advisory committee and a member of the editorial advisory board of the Life Science Leader. Ms. Williams received a B.S. in Nursing from the University of Iowa and an M.B.A. from the Washington University John Olin School of Business.

Seung Suh Hong, Ph.D. has served as a member of our board of directors since June 2019. Dr. Hong has served as Divisional Head of Daewoong Pharmaceutical Co., Ltd., a pharmaceutical company, since June 2025. Dr. Hong has served as a consultant to a number of biopharmaceutical companies since March 2019, including through MediRapha, a consulting firm for which he was the Chief Executive Officer. Previously, Dr. Hong served as Vice Chairman of the board of directors, Chief Scientific Officer and Chief Operating Officer of CentricsBio, Inc., a biotechnology company focused on immunotherapeutics, from January 2025 to May 2025; as Chief Executive Officer of Rophibio, Inc., a biopharmaceutical company from March 2023 to December 2024 and as its Senior Advisor from February 2022 to March 2023; as President and Chief Operating Officer of CELLemedy, a biopharmaceutical start-up company, from January 2021 to February 2023; and as Senior Advisor for Novelgen, a biopharmaceutical company, from April 2020 to February 2023, in South Korea. From April 2002 to March 2021, Dr. Hong served in various capacities at Celltrion Inc., a biopharmaceutical company, including as Senior Consultant at Celltrion Healthcare from February 2020 to March 2021; as President and Chief Executive Officer of Celltrion Healthcare Japan from August 2016 to January 2019; as President and Chief Executive Officer of Celltrion Healthcare from November 2014 to December 2015; and as President of Research and Development and Global Business Development from April 2002 to November 2014; Dr. Hong also served as Director at Sam Yang Corporation, a food and pharmaceutical company from April 1981 to April 2002. Dr. Hong received a B.S. in Agricultural Chemistry, an M.S. in Industrial Enzymology, and a Ph.D. in Enzymology and Fermentation from Seoul National University. Dr. Hong also participated in post-doctoral studies at the University of Wisconsin-Madison. Dr. Hong has significant executive leadership, operations and strategy, research, medical technology development and life sciences industry experience.

On June 10, 2026, the Board appointed Jason Robins, the Company's interim Chief Financial Officer, to serve as the Chief Financial Officer. Mr. Robins is continuing to serve as the Company's principal financial officer and principal accounting officer. Mr. Robins, has served as the Company's interim Chief Financial Officer since January 20, 2026. Mr. Robins had previously served as the Company's Senior Vice President, Finance, since January 2025, where he managed accounting, reporting, financial planning and analysis, and corporate planning. From October 2020 to December 2024, Mr. Robins served as Vice President, Finance, of Fusion Pharmaceuticals Inc., a biopharmaceutical company acquired by AstraZeneca in June 2024. Mr. Robins received a Bachelor of Science from Babson College, a Master of Science from the Harvard-MIT Division of Health Sciences and Technology, and a Master of Business Administration from the MIT Sloan School of Management.

Todd D.C. Anderman has served as our Chief Legal Officer and Secretary since October 2024. Prior to joining Ocular Therapeutix, Mr. Anderman provided general legal services to biotechnology companies from February 2024 to September 2024 as founder and sole member of Anderman LLC, a legal practice. He previously served as Senior Vice President, Chief Legal Officer and Secretary of IVERIC from January 2023 until August 2023; as Senior Vice President, General Counsel and Secretary from January 2021 to December 2022; as Vice President, General Counsel and Secretary from February 2018 to December 2020 and in other roles since he joined IVERIC in April 2015. Prior to joining IVERIC, he served as a Counsel and a Senior Associate in the Corporate group of Wilmer Cutler Pickering Hale and Dorr LLP, a law firm, from April 2012 to April 2015; and an Associate in the Corporate group of Cravath, Swaine & Moore LLP, also a law firm, from October 2007 to April 2012. Mr. Anderman received a B.A. in Government and Philosophy from the College of Arts & Sciences at Cornell University and a J.D. from the University of Pennsylvania Law School.

Namrata Saroj, OD has served as our Chief Business Officer since November 2024. Since July 2020, Dr. Saroj has served as Co-Founder and Chief Medical Adviser at Clinical Trials Resource Group, providing contract resource organization services for ophthalmological human clinical trials; and since July 2018, Dr. Saroj has served as Founder and Principal at All Eyes Consulting, LLC, providing consulting services to pharmacy, biotechnology and medical technology companies. Dr. Saroj received an O.D. from the University of California, Berkeley, a B.S. in Optometry from the University of California, Berkeley and a B.A. in Biochemistry, from Whittier College.

David Robinson has served as our Global Chief Commercial Officer since January 2026. Prior to joining us, Mr. Robinson served as Chief Marketing Officer, Global Ophthalmology at Merck & Co., Inc., a pharmaceutical company, from April 2025 to January 2026, where he was responsible for the global launch plan for two new product candidates following Merck's acquisition of EyeBio. Prior to that, Mr. Robinson served as Senior Vice President, Specialty Consulting at Eversana from November 2021 to December 2024, following Eversana's acquisition of Protean LLC, where he had served as Partner from January 2018 to November 2021, providing consulting services to companies within the pharmaceutical and biotechnology industries. Prior to his consulting work, Mr. Robinson served in multiple commercial leadership roles at Regeneron Pharmaceuticals, Inc. from May 2011 to January 2018, most recently as Vice President, Sales, Field Access and Reimbursement, where he developed and executed the strategic plan to launch EYLEA (aflibercept), Regeneron's first product to market. Mr. Robinson received a B.S. in Business Administration from Appalachian State University.

Jeffrey Heier, M.D. has served as our Chief Scientific Officer since February 2024. Dr. Heier previously served as a member of our board of directors from September 2015 until February 2024. Since 1998, Dr. Heier has worked as a vitreoretinal specialist at Ophthalmic Consultants of Boston, or OCB, a large multi-specialty ophthalmology practice with several offices in the Boston, Massachusetts area, where he served as Co-President and Medical Director from 2016 to 2020, and has served as the Director of Vitreoretinal Service since 2009 and the Director of Retina Research since 2011. He is a partner of the Boston Eye Surgery and Laser Center and was previously a partner of the Cape Cod Eye Surgery and Laser Center and the Plymouth Eye Surgery and Laser Center. Dr. Heier has served in leadership roles of several professional organizations including as an executive board member and past president of each of the New England Ophthalmological Society and the Retina Society, and he previously served as a board member of American Society of Retina Specialists from 2011 to 2024. Dr. Heier holds a B.S. in Biochemistry from Brandeis University and an M.D. from the Boston University School of Medicine. Dr. Heier completed his vitreoretinal fellowship at OCB / Tufts School of Medicine and served as a physician in a Combat Support Hospital in the Persian Gulf War, for which he was awarded a Bronze Star.